Fig 1: AKS-452-Induced mouse IgG Isotypes analysis. BALB/c mice 6 to 8 weeks of age were immunized with two doses of AKS-452 (human IgG1 Fc-SP/RBD fusion protein) at a 10 µg dose level formulated with or without Montanide ISA 720 adjuvant. Serum was collected on Days 14 and 35 after the first (administered on Day 0) and second (administered on Day 21) doses, respectively, and evaluated for anti-SP/RBD IgG titer isotypes, (A) IgG1 (Th2 type), (B) IgG2a (Th1 type), and (C) IgG2b (Th1 type) via isotype-specific ELISAs (using a mouse serum reference curve). Group means were compared using a parametric mixed model ANOVA of the log transformed data conducted in SAS software (model effects: adjuvant, day and random animal); * p < 0.05, ** p < 0.01, *** p < 0.001 relative to the respective dose level without adjuvant at each timepoint.